A Trial to Assess Safety, Tolerability, and Pharmacokinetics of AN01 Inhalation Powder in Healthy Participants

NCT07554365 | Recruiting Phase 1

• 1 other identifier: AN-HV-1001
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

AN01 is a selective small-molecule dual inhibitor of phosphodiesterase 3 and 4 (PDE3/4). As a potential new therapy for COPD, AN01 is expected to serve either as a monotherapy for COPD or as adjunctive therapy to current inhaled standard treatments, potentially generating synergistic complementary effects in patients requiring additional therapeutic options. The primary objective of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple doses of AN01 in healthy participants.

Conditions

Healthy Participants Study; Healthy Volunteer

Outcome Measures

Primary Outcomes (7)

• Incidence, severity, relationship to the investigational drug, and types of adverse events and serious adverse events

  Day 1 - Day 14

• Number of participants with abnormal clinically significant physical examination (PE) results following study drug administration

  Day 1 - Day 14

• Number of participants with abnormal clinically significant vital signs following study drug administration

  Day 1 - Day 14

• Number of participants with abnormal clinically significant clinical laboratory results following study drug administration

  Day 1 - Day 14

• Number of participants with abnormal clinically significant spirometry parameters following study drug administration

  Day 1 - Day 6

• Number of participants with abnormal clinically significant respiratory assessment findings following study drug administration

  Day 1 - Day 6

• Number of participants with abnormal clinically significant 12-lead electrocardiogram (ECG) parameters following study drug administration

  Day 1 - Day 14

Secondary Outcomes (7)

• PK parameter assessed by serum AN01 concentration at specified timepoints for area under curve (AUC)

  Day 1 - Day 9

• PK parameter assessed by serum AN01 concentration at specified timepoints for maximum plasma concentration (Cmax)

  Day 1 - Day 9

• PK parameter assessed by serum AN01 concentration at specified timepoints for time to peak concentration (Tmax)

  Day 1 - Day 9

• PK parameter assessed by serum AN01 concentration at specified timepoints for terminal elimination half life (t1/2)

  Day 1 - Day 9

• PK parameter assessed by serum AN01 concentration at specified timepoints for apparent clearance volume (CL/F)

  Day 1 - Day 9

Study Arms (2)

AN01

EXPERIMENTAL

Escalating multiple doses of AN01

Drug: AN01

Placebo

PLACEBO COMPARATOR

Escalating doses of matching placebo

Drug: Placebo

Interventions

AN01 DRUG

Active study drug

AN01

Placebo DRUG

Placebo

Placebo

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy adults ≥18 and ≤60 years (inclusive).
• Body Mass Index (BMI) ≥18 and ≤32 kg/m2 (inclusive).
• Participants who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, spirometry, and electrocardiogram (ECG).
• Non-smokers or former smokers who have quit for ≥2 years with a prior smoking history of \<5 pack-years (pack-years defined as = cigarettes per day × years smoked; 1 pack = 20 cigarettes).
• Female participants must be non-pregnant and non-lactating, and, surgically sterile, use highly effective contraceptive methods from Screening until at least 30 days after the last dose of study drug, or post-menopausal for ≥12 months.
• Male participants must be surgically sterile, abstinent, or their partner must be surgically sterile, or if engaged in sexual relations with a woman of childbearing potential (WOCBP), the male participant and his partner must use an acceptable, highly effective contraceptive method from Screening until at least 90 days after the last dose of study drug.

You may not qualify if:

• History of clinically significant (as per Investigator's judgment) upper respiratory disease or history of any significant pulmonary disease including, but not limited to, asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and history of previous tuberculosis exposure with positive interferon gold test (without actual infection).
• Participants with any history of, or active, clinically significant disease (e.g., cardiovascular disease, chronic liver disease, psychiatric medical history, renal disease) that could interfere with the interpretation of the study results or compromise the health of the participant based on the judgment of the Investigator.
• Administration of vaccines/immunizations and/or boosters within 8 days prior to first dosing or if planned during the study.
• Any history of active infection at the time of Screening and/or within 28 days prior to first dosing.
• Any prior participation in a study with an investigational drug or device involving a biological targeted therapy, where final administration of the investigational drug or utilization of the device occurred within 24 weeks prior to first dosing.
• History of migraine headaches requiring prescription medication or occurring more than 2-4 times per month within the past 6 months.
• Use of non-tobacco vaping within 12 months prior to Screening.
• Use of any tobacco and/or inhaled marijuana product within 2 years prior to Screening.

Sponsors & Collaborators

• AirNexis Therapeutics, Inc.: lead

Study Sites (1)

Site 103

Adelaide, South Australia, 5000, Australia

RECRUITING

Central Study Contacts

Clinical Trial Manager

CONTACT

4089307893; hdo@airnexis.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 2, 2026
• First Posted: April 28, 2026
• Study Start: May 1, 2026
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): June 1, 2026
• Last Updated: May 5, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

AU (1)